Ipsen names new Head of Global Medical Affairs

pharmafile | February 8, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen 

French pharmaceutical firm Ipsen has announced its recruitment of Dr Sotirios Stergiopoulos as its Senior Vice President and Head of Global Medical Affairs. Stergiopoulos joins the company from Baxalta, a subsidiary of Shire, where he served as Vice President, Head of Global Medical Affairs Oncology.

The appointment was revealed simultaneously with the news that Harout Semerjian has joined Ipsen as its President, Head of Speciality Care International Region and Global Finances.

Throughout his career, Stergiopoulos has held senior medical director positions at Celgene, Novartis and Bayer, preparing him well for his new role with Ipsen. Stergiopoulos will report to Dr Alexandre LeBeaut, current interim head of Ipsen R&D.

LaBeaut commented: “Sotirios brings extensive experience in directing global medical affairs strategies along with a solid expertise in oncology drug development that includes immunology drugs and targeted agents across different tumour indications. Sotirios will play an important role within the R&D leadership team, particularly as we continue to strengthen Ipsen’s oncology portfolio.”

Related Content

Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment

Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) …

FDA accepts Ipsen’s NDA for ultra-rare genetic disorder drug

The FDA have accepted Ipsen’s New Drug Application (NDA) for palovarotene, an oral, investigational, selective …

Latest content